Weihansi Biopharma Raises ￥100M in Series Pre-B Funding Round

(VCBeat) May. 10, 2021 -- Shanghai Weihansi Biopharmaceutical Technology Co., Ltd. ("Weihansi Biopharma") announced the closing of a Series Pre-B financing of nearly RMB100 million exclusively from Huayao Capital. The funds raised by this round will be used to further promote the research and development of Weihansi Biopharma's core products, expand the product pipelines, and improve the business layout in the industrial chain.

Previously, Weihansi Biopharma has received several rounds of investment from well-known investors in the industry, such as Matrix Partners China and WisdoMont Asset Management.

Weihansi Biopharma was founded in 2016, is a national high-tech enterprise engaged in genetic disease detection in the field of reproductive health. It focuses on the study of genetic testing technology and is committed to the innovation of advanced genetic testing technology and diversified platform around the block for genetic variation.

At present, Weihansi Biopharma has obtained 31 patents, 33 software patents, 43 trademarks, and 28 Class II and Class III medical device registration certificates. Relying on its strong technical innovation ability, Weihansi Biopharma has established diverse genetic testing technology platform, and actively carry out commercial cooperation and scientific research cooperation on various testing scenarios such as birth defect prevention and screening (three-level prevention and control system), assisted diagnosis of genetic diseases, infertility and assisted reproduction testing, and kinship testing.

Gao Pengfei, the founder of Weihansi Biopharma, is one of the earliest practitioners of the NGS market and third-party clinical cellular and molecular genetics in China. He majors in the field of biotechnology and has rich sales and management experience. He said, " Weihansi Biopharma is striving to build a development ecosystem that integrates the advantages of the advanced genetic disease technology innovation platform, large biological sample numbers, standardized testing operation model and good qualification. The company aims to become a leading company in the field of genetic testing and a medical biotechnology company with long-term influence."